Akari Therapeutics plc held a special general meeting of shareholders on March 2, 2026. Shareholders approved a proposal to approve the exercisability of Series G warrants and placement agent warrants and the issuance of the underlying ADSs and ordinary shares related to financings that closed on December 17, 2025 and January 20, 2026. Shareholders also approved proposals to approve the exercisability of pre-funded warrants and Series G warrants and the issuance of the underlying ADSs and ordinary shares related to a private placement that closed on December 23, 2025, and approved proposals to approve the exercisability of pre-funded warrants and note exchange warrants and the issuance of the underlying ADSs and ordinary shares related to a note exchange that closed on December 17, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-008570), on March 02, 2026, and is solely responsible for the information contained therein.